The LanP sequences were aligned in ClustalX 1 using default parameters with iteration at each alignment step, and the alignments were manually fine-tuned afterwards. Bayesian inference was used to calculate posterior probability of clades utilizing the program MrBayes 2 (version 3.2). Final analyses consisted of two sets of eight chains each (one cold and seven heated), run to reach a convergence with standard deviation of split frequencies <0.005. Posterior probabilities were averaged over the final 75% of trees (25% burn in). The analysis utilized a mixed amino acid model with a proportion of sites designated invariant, and rate variation among sites modeled after a gamma distribution divided into eight categories, with all variable parameters estimated by the program based on BioNJ starting trees. Accession numbers are listed in the Supplementary Table 1 .
SDS-PAGE analysis (Supplementary
). Aliquots were frozen in liquid nitrogen for future use and stored at -80 °C.
Cloning, expression, and purification of His 6 -ElxA and mutant variants
The cloning of the gene encoding ElxA into pET28b is described elsewhere. 3 The ElxA leader peptide variants were constructed using QuikChange mutagenesis following a previously described method. 4 The his 6 -elxA-pET28b was used as a template to introduce the different mutations by PCR using the corresponding primer pair listed in the Supplementary Table 5 . A typical PCR reaction consisted of 1X HF Buffer, 0.2 mM DNTP, 1 M forward and reverse primers, 10 ng template DNA, 3% (v/v) DMSO and 0.02 U L -1 Phusion polymerase (NEB). After PCR, reactions were incubated at 37 C for 2 h with DpnI (5 U). After treatment with DpnI, samples were purified using the QIAquick PCR purification kit (Qiagen). An aliquot of 10 L was used to transform E. coli DH5cells using the heat shock method and cells were plated on LBA plates supplemented with kan (50 g mL -1 ). Plates were incubated at 37 C overnight. A single colony was inoculated in LB supplemented with kan, grown at 37 C overnight, and plasmid was extracted using the QIAprep spin mini prep kit (Qiagen). The desired mutations were verified by DNA sequencing.
Overexpression and purification of wild type ElxA and mutant variants was carried out using a previously described method with minor modifications. 3 An aliquot of 50 ng of recombinant DNA from wild type ElxA and each of the mutants described above was used to transform 50 L of electrocompetent E. coli BL21 (DE3) cells and plated on LBA supplemented with kan (50 g mL -1 ) at 37 °C overnight. A single colony was used to inoculate a starter inoculum of LB supplemented with kan and incubated at 37 °C for 12 h. After the incubation period, 6 L of Terrific Broth (TB) supplemented with kan, and glycerol (4 mL L -1 ), were inoculated with the starter culture to obtain an initial OD 600 of 0.025. Flasks were incubated at 37 °C, 250 rpm, and peptide expression was induced at 18 °C, 250 rpm for 18 h with 1.0 mM IPTG when the OD 600 reached 1.0. Cells were harvested by centrifugation (6,976 xg, 20 min, 4 °C), resuspended in 30 mL of LanA Buffer 1 (6 M guanidine hydrochloride, 20 mM NaH 2 PO 4 pH 7.5, 500 mM NaCl and 0.5 mM imidazole) and lysed by sonication (35% amplitude, 4.0 s pulse, 9.9 s pause, 15 min). Cell debris was removed by centrifugation (22789 xg, 30 min, 4 °C) and supernatant was filtered through a 0.45 m syringe filter unit. Purification was carried out using a 5 mL HisTrap column pre-packed with Ni Sepharose TM . After loading the supernatant into the column, the column was washed with 10 column volumes (CV) of LanA Buffer 1 followed by 10 CV of LanA Buffer 2 (4 M guanidine hydrochloride, 20 mM NaH 2 PO 4 pH 7.5, 300 mM NaCl and 30 mM imidazole) to remove any non-specifically bound proteins, followed by peptide elution in 3 CV of LanA Elution Buffer (4 M guanidine hydrochloride, 20 mM Tris HCl pH 7.5, 100 mM NaCl, 1 M imidazole). To remove excess salts, the peptide was purified by reversed phase high performance liquid chromatography (RP-HPLC) using a C 4 Waters Delta Pak cartridge column with a linear gradient of 2%
Fractions were analyzed for the desired peptide by matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Fractions containing peptide were freeze dried using a lyophilizer (Labconco) and stored at −20 °C. The purity of each peptide was assessed by analytical HPLC.
Cloning, expression, and purification of His 6 -NisA and mutant variants
The cloning of the gene encoding NisA into pRSF Duet-1 is described elsewhere. 5 The NisA leader peptide variants were constructed using QuikChange mutagenesis. The his 6 -nisA-pRSF Duet-1 plasmid was used as a template to introduce the different mutations by PCR using the corresponding primer pair listed in the Supplementary Table 5 . PCR conditions, overexpression, and purification of peptides were performed as described above.
Determination of ElxP kinetic parameters
The kinetic parameters of MBP-ElxP were determined using an HPLC based assay following a previously described method. 6 The peptidase activity of tagged ElxP was assayed in a 100 L reaction mixture containing 50 mM Tris pH 8.0, and various concentrations of wild type His 6 -ElxA or mutant variants. The reaction was started by adding MBP-ElxP to a final concentration such as to consume less than 10% of the initial substrate concentration in the time frame of the assay. The enzyme concentration ranged from 0.25 M to 1 M. The reaction was incubated at room temperature and quenched in 0.1% (v/v) TFA and 5 mM tris(2-carboxyethyl)phosphine (TCEP) at different time points. The reactions were loaded on a Hypersil Gold C 4 (250 x 4.6 mm, 5  analytical column (Thermo Fisher Scientific) connected to an Agilent 1260 Liquid Chromatography (HPLC) system (Agilent Technologies). Product formation was detected by monitoring the increase in the peak area of the leader peptide at 220 nm (Supplementary Figure 2 ). The leader peptide was separated from the unmodified core and precursor peptide using a linear gradient from
over 30 min at a flow rate of 1 mL min -1 at room temperature. The concentration of the leader peptide was calculated by converting the area under the leader peptide peak to leader peptide concentration using a calibration curve made from purified leader peptide ( Supplementary Figure 3 ). Rates of leader peptide formation were then plotted against substrate concentration and the resulting graph was fit to the Michaelis-Menten equation. Values were plotted as the average and standard error of two independent experiments. Reactions were performed with tagged enzymes and substrates unless otherwise noted.
Synthesis of ElxO substrate analogs
Peptides were synthesized on a 0.1 mmol or 0.15 mmol scale by Fmoc-based SPPS using a PS3 peptide synthesizer (Protein Technologies) or an Apex SC-396 Peptide Synthesizer (Advanced Chemtech). Fmoc groups were removed during the deprotection steps with 20% (v/v) piperidine in N,N-dimethylformamide (DMF) for 3 × 3 min. Coupling of the amino acids was performed for 1-1.5 h with 0.5 or 0.75 mmol (five equiv.) of each Fmoc-AA and using DMF as solvent and 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3tetramethylaminium hexafluorophosphate (HCTU) with 0.4 M N-methylmorpholine (NMM) or hydroxybenzotriazole (HOBt) with diisopropylcarbodiimide (DIC) as activating reagents. Coupling reactions of pyruvic acid or -ketobutyric acid were performed twice for 1-1.5 h using 5 equiv. of acid in the presence of HOBt and DIC. After completion of synthesis, peptidyl-resins were washed with DMF and ethanol, and dried under reduced pressure. Peptides were cleaved from the resins using a mixture of TFA/water/phenol (90:5:5) for 2 h. For Pyr-MAIVK a cleavage cocktail containing TFA/water/phenol/thioanisole /mercaptoethanol (82.5:5:5:5:2.5) was used, and for Pyr-YAIVK, Pyr-TAIVK, Pyr-RAIVK, and Obu-RAIVK a cleavage mixture of TFA/water/phenol/thioanisole (85:5:5:5) was used. The cleavage solutions were evaporated in a rotary evaporator to remove TFA and the peptides were precipitated from the solution with cold diethyl ether. The precipitated materials were resuspended in 0.1% (v/v) TFA in acetonitrile/water (50:50) and lyophilized to dryness. The synthesis of Glx-AAIVK was performed by oxidation of SAAIVK (5 mM) with sodium periodate (10 mM) in sodium phosphate buffer (40 mM, pH 7.5) for 5 min, followed by quenching with sodium sulfite (40 mM). 7 The peptides were purified by semi preparative reversed phase HPLC using an Agilent 1200 instrument equipped with an Eclipse XDB-C18 column (9.4 mm x 250 mm, Agilent) or a Synergi Fusion-RP column (9.4 mm × 150 mm, Phenomenex) and a variable wavelength detector set at 220 nm. The mobile phase was 0.1% (v/v) formic acid in water (solvent A) and acetonitrile (solvent B). A gradient of 2-30% (v/v) solvent B in solvent A and a flow rate of 4 mL min -1 were used. The masses of the purified peptides were determined by ESI-MS using a Waters ZMD quadrupole Instrument at the Mass Spectrometry Laboratory of the University of Illinois at Urbana-Champaign.
Production of dihydrolactocin S
Synthetic lactocin S (50 M), obtained from Prof. J. Vederas (University of Alberta), 8 was incubated with His 6 -ElxO (50 M) and NADPH (10 mM) in assay buffer (100 mM HEPES, 500 mM NaCl, pH 7.5) at room temperature for 12 h. The formation of reduced peptide was confirmed by LC-MS using a Waters SYNAPT TM mass spectrometry system equipped with a ACQUITY UPLC ® , an ESI ion source, a quadrupole time-of-flight detector, and a ACQUITY Bridged Ethyl Hybrid (BEH) C8 column (2.1 mm × 50 mm, 1.7 µm, Waters). A gradient of 3-97% (v/v) B (0.1% (v/v) formic acid in methanol) in A (0.1% (v/v) formic acid in water) over 12 min was used.
Determination of the ElxO x-ray crystal structure
Apo-ElxO was concentrated to a final concentration of 0.4 mM by centrifugal filters, and incubated with five-fold excess of freshly prepared NADPH. The solution was incubated on ice for 2 h prior to crystallization. Crystals of the ElxO wild type enzyme in complex with NADPH were grown using the hanging drop vapor diffusion technique. Commercially available sparse matrix screens were used to identify initial crystallization conditions using the Hampton Natrix crystallization screen. The initial condition (Natrix 39) was optimized to 0.1 M ammonium acetate, 0.02 M magnesium chloride, 0.05 M HEPES-Na (pH 7.5), 8% (v/v) PEG 800, and 5% (v/v) glycerol. Crystals were obtained by adding 1 L of the protein to an equal volume of the crystallization mother liquor equilibrated against the same solution at 9 °C. Crystals were vitrified by soaking in crystallization condition supplemented with 30% (v/v) glycerol prior to direct immersion in liquid nitrogen. All X-ray diffraction data were collected at the Life Sciences Collaborative Access Team (Sector-21) Argonne National Laboratory (Lemont, IL).
The diffraction data was indexed and scaled using HKL2000 9 to a limiting resolution of 1.85 Å. The coordinates from three models (PDB ids: 2HQI, 2UVD, and 2CFC) were superimposed to generate a search model for molecular replacement. All water and ligand atoms from the search model were deleted, and non-conserved amino acid side chains reduced to alanine. A five-fold redundant native dataset for the ElxO-NADPH complex crystal was used.
Following rigid body refinement of the initial MR solution, phases from the resultant model were further improved by two fold density averaging allowing for a significant portion of the model to be manually rebuilt using XtalView. 10 Further manual fitting was interspersed with automated rebuilding using ARP/wARP 11 and rounds of refinement using REFMAC5. 12, 13 Cross-validation, using 5% of the data for the calculation of the free R factor, 14 was utilized throughout the model building process in order to monitor building bias. Although clear density for NADPH could be observed prior to crystallographic refinement, the ligand was manually built into the model only after the free R factor dropped below 30%. The stereochemistry of the models was routinely monitored throughout the course of refinement using PROCHECK. 15 Crystallographic data summary for ElxO is presented in Supplementary Table 4 . Supplementary Table 5 . Oligonucleotides used in this study 
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